The Model Index
240 major releases since ChatGPT

Trends

Who is shipping, how fast, and how much more AI can do each year: from release pace to the length of task an agent finishes on its own.

86in 2026 so far
10daysbetween releases in 2023
2daysbetween releases in 2026

Every major releaseone lane per lab

UNITED STATESCHINAEUROPEOpenAIGoogleAnthropicxAIMetaMicrosoftNVIDIAAmazonTMThinking MachinesAlibabaDeepSeekZhipuMoonshotMiniMaxByteDanceTencentXiaomiBaiduStepFunAnt GroupMeituanMistral2023202420252026

A release is the first public announcement or availability. Point updates and minor snapshots are left out. Filled dots are closed models, rings are open weights.

Releases per quarterclosed and open

01020304050Q120234Q22Q36Q411Q120249Q213Q38Q415Q1202518Q220Q321Q426Q1202618Q227Q341Q4
4.0minGPT-4, March 2023
16h+Claude Mythos Preview, Apr 2026
~7×growth per year

Longest task an agent finishes on its ownMETR 50% time horizon · log scale

before ChatGPT3 sec30 sec4 min1 h8 h16 ha minutea coffee breakan houra working daytwo working days201920212023202420252026GPT-4o1GPT-5Claude Opus 4.6Mythos Preview

METR times tasks on skilled people, then measures which ones an agent completes half the time. Beyond 16 hours its current tasks can no longer measure reliably, so the top reads "16 h or more".

Tests built to last years fall in months30 tests · record score over time

0%100%

Each strip darkens as the best score climbs; solid ink means the field has outgrown the test. Open any row for its record history. Outgrown: the record has passed 90%. Replaced: a newer version exists. Gone quiet: no new record in a year.

Capability firsts59 moments a new ability appeared

2023202420252026ReasoningMaths & scienceCodingAgentsSecurityMemorySensesMedicine & biologyRoboticsOpen weightsUoRSESAFIXMADEMIAIUoUAAMAMIPIUHIM
Sep 202659 of 59 · Medicine & biology

AI-found target and AI-made molecule reach Phase III

Insilico announced the first patient dosed in a 52-week Phase III trial of rentosertib for idiopathic pulmonary fibrosis. It describes the drug as the first candidate with both an AI-identified target and an AI-generated molecule to reach Phase III, after positive Phase IIa results in Nature Medicine in 2025.

Rentosertib (ISM001-055)news-medical.net ↗